摘要:
The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent or treat asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, septic shock, or multiple sclerosis, and to pharmaceutical compositions that contain the compounds of Formula (I).
摘要:
Diazepinoindoles of formula (I), ##STR1## wherein A is mono- to trisubstituted aryl or heteroaryl, and B is an --OR.sub.1 or --NR.sub.2 R.sub.3 group where R.sub.1, R.sub.2 and R.sub.3 are particularly hydrogen, and racemic forms, enantiomers and pharmaceutically acceptable salts thereof, as phosphodiesterase IV inhibitors, are disclosed.
摘要:
(−)E-2-(3,4-dichlorocinnamyl)-1-cyclo-propylmethyl-piperidine of formula I: and its pharmaceutically acceptable salts, is useful for treating diarrhea in mammals. Also disclosed are pharmaceutical compositions, processes for preparing compounds of formula (I) and intermediates useful for preparing compounds of formula I.
摘要:
The invention relates to diazepinoindoles of formula: ##STR1## in which R is hydrogen, lower alkyl or lower alkoxy; A is aryl or nitrogen-containing heteroaryl, each of which is optionally substituted by from one to three groups of halogen, lower alkyl, haloalkyl, lower alkoxy and acetamido, or their racemic forms, isomers or pharmaceutically acceptable salts, wherein for the racemic forms of the (S) configuration, A is not phenyl, haloalkyl, or 2-indolyl when R is hydrogen, and for the racemic forms of the (R) configuration, A is not 2-indolyl when R is hydrogen. Also, the invention relates to a method for inhibiting cyclic nucleotide phosphodiesterase activity by administering these compounds to a subject in an amount which is therapeutically effective to inhibit cyclic nucleotide phosphodiesterase activity.
摘要:
New cycloalkylalkylamines which are sigma-receptor ligands of formule (I) ##STR1## in which: R.sub.1 is H or lower alkyl; X and Y are H, OH, lower alkyl, lower alkoxy, halogen or nitrile; V.sub.1 and V.sub.2 together form a double bond attached to an oxygen atom or to a hydroxyimino radical, or are linked as an ethylenedioxy chain; A represents a valency bond, an oxygen atom, a methylene or an ethylene group; m is equal to 0, 1 or 2; n has the value of an integer from 1 to 5. Psychotropic drug which is also useful in gastroenterology.
摘要:
The present invention relates to propanamines of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted in an identical or different manner with halogen atoms, or lower alkyl, lower haloalkyl or lower alkoxy radicals;R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkyalkyl radical,R5 is a 5-to 7-membered cycloalkyl radical or a phenyl radical, andW represents a heterocycle .dbd.C[Q--(CH.sub.2).sub.n --Q] in which Q is an oxygen or sulfur atom and n is 2 or 3,and their acid addition salts with pharmaceutically acceptable acids. The invention also relates to antidiarrheal pharmaceutical compositions comprising the claimed propanamines.
摘要翻译:本发明涉及通式(I)的丙胺,其中:R 1是任选地以与卤素原子相同或不同的方式单,二或三取代的苯基,或低级烷基低级卤代烷基 或低级烷氧基; R2是低级烷基,R3和R4是氢原子或低级烷基,低级烯基或低级环烷基,R5是5-至7-元环烷基或苯基,W表示杂环= C [ Q-(CH2)nQ]其中Q是氧或硫原子,n是2或3,以及它们与药学上可接受的酸的酸加成盐。 本发明还涉及包含所要求保护的丙胺的止泻药物组合物。
摘要:
Enantiomers of (S) configuration of formula (I) ##STR1## in which R is H or methyl, with antiallergic and in particular antihistaminic activity, useful as medicinal products.
摘要:
A compound which is a propanamine of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted,or is a 5- or 6-membered monocyclic heteroaryl radical in which the single heteroatom is nitrogen, oxygen or sulfur,R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkylalkyl radical,or, together with the nitrogen atom to which they are attached, form a saturated 5- to 6-membered heterocycle comprising only one heteroatom,R5 is a 5- to 7-membered cycloalkyl radical, a phenyl radical or a 5- or 6-membered monocyclic heteroaryl radical,and W representsa group .dbd.CH--QH,or a heterocycle .dbd.C[Q--(CH2)n--Q],or a group .dbd.C.dbd.Q, in which groupsQ is an oxygen or sulfur atom,n has the value 2 or 3,W being .dbd.C.dbd.Q only when R3 and R4 are not both hydrogen, and their additions salts with pharmaceutically acceptable acids.A pharmaceutical composition comprising a compound of general formula (I) with the above definitions for the treatment of diarrheal states.
摘要翻译:作为通式(I)的丙胺的化合物,其中:R 1是任选被一个,二或三取代的苯基,或是5或6元单环杂芳基,其中 单个杂原子是氮,氧或硫,R2是低级烷基,R3和R4是氢原子或低级烷基,低级烯基或低级环烷基烷基,或者与它们相连的氮原子一起形成 饱和的5至6元杂环,仅包含一个杂原子,R 5为5-至7-元环烷基,苯基或5-或6-元单环杂芳基,W表示基团= CH-QH, 或杂环= C [Q-(CH 2)nQ]或基团= C = Q,其中基团Q是氧或硫原子,n具有值2或3,W仅当R 3为 和R4不同时为氢,并且它们与药学上可接受的酸相加。 一种药物组合物,其包含具有上述定义用于治疗腹泻状态的通式(I)的化合物。
摘要:
Novel derivatives of midecamycine, of the formula: ##STR1## wherein X represents an oxygen atom or a sulphur atom, R.sub.1 represents a straight or branched alkyl group, an alkenyl group or an aryl group, R.sub.2 represents a hydrogen atom or a lower acyl group, the dotted lines represent the possible presence of double bonds, it being understood that the 2 double bonds at the 10,11 position on the one hand and the 12,13 position on the other either exist simultaneously or neither of them exists, which give by oral administration plasma rates which are higher than midecamycine and which lack its bitter taste, together with their process of preparation.